Drugs / Lidocaine-Prilocaine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02640183 | Sep 2015 → Mar 2016 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02380742 | Jul 2015 → Feb 2016 | — | Loyola University | Completed | Met primary |
| Phase 2 | NCT01673542 | Aug 2012 → May 2013 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03146000 | May 2017 → Aug 2018 | puerperal disorder | Assiut University | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07778043 | Aug 2026 → Jul 2028 expected | myofascial pain syndrome, pelvis syndrome | Women and Infants Hospital of Rhode Island | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07288021 | Feb 2024 → Feb 2026 overdue | — | Bnai Zion Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04467125 | Jan 2020 → May 2023 | — | Augusta University | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT02666534 Background | Jan 2012 → Dec 2015 | squamous cell carcinoma | Dong-A University | Completed | No outcome recorded |
| Phase 1 | NCT03320447 Background | Oct 2011 → Oct 2016 | Bowen disease of the skin | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT04473820 Comparator | Feb → Apr 2024 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04339348 Comparator | Apr 2020 → Feb 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04340778 Comparator | Apr → Aug 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT01094015 Comparator | Jul 2007 → Jan 2009 | — | Consorci Sanitari de Terrassa | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lidocaine-prilocaine | “Lidocaine-Prilocaine (EMLA®) Cream in Hysteroscopy Practice: A Prospective Randomized Non-blinded Controlled Study” NCT02640183 ↗ |
| Known as | EMLA | “The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area...” NCT03320447 ↗2“5% lidocaine 25 mg-prilocaine 25 mg/g cream (EMLA®)” NCT02640183 ↗ “EMLA (lidocaine-prilocaine) Cream” NCT07778043 ↗ |
| Route | Topical | “Application, with a swab of the anesthetic cream ectocervix level.” NCT01094015 ↗ |